Monitoring and assessment should include: Thyroid function tests (TSH, free T4) approximately 68 weeks after starting or adjusting levothyroxine, then at least annually once stable HbA1c measurements every 36 months to assess long-term glucose control Regular blood glucose monitoring as advised by your diabetes care team Annual kidney function tests (eGFR) and urine albumin-to-creatinine ratio Annual lipid profiles and cardiovascular risk assessment Monitoring for symptoms of either condition worsening Lifestyle modifications benefit both conditions significantly
How wonderful would it feel to walk out with new confidence, loving your very own skin
The first GLP-1 receptor agonist, exenatide, was approved by the US regulators, the FDA, in 2005, marking a significant advance in diabetes treatment
Bupropion is an antidepressant, and for patients with mild-to-moderate depression alongside obesity, Contraves bupropion component may offer a secondary benefit on mood
Timely treatment of kidney infections is essential to prevent these complications
